The rapidly changing landscape and evolving best practices for developing clinical practice guidelines (CPGs) provided an opportunity in 2013 for the National Heart, Lung, and Blood Institute (NHLBI) to examine and refocus its agenda in the domain of CPG development. 1 After extensive consultations with internal and external stakeholders and recommendations from the National Heart, Lung, and Blood Advisory Council, the NHLBI made a commitment to primarily support rigorous systematic evidence reviews and evidence syntheses that frontline health care providers, health professional organizations, and relevant stakeholders could use to create new or update existing CPGs. 1 Importantly, the advisory council also recommended NHLBI's continued engagement in the production of CPGs primarily by partnering with professional societies or by creating standalone guidelines if the need is great and there is no other sponsoring organization or group of organizations. 1 The first application of this refocused agenda was in the systematic review reports on blood pressure, 2 cholesterol, 3 cardiovascular risk assessment, 4 lifestyle interventions, 5 and overweight and obesity 6 that informed the development of related cardiovascular CPGs from the American Heart Association, American College of Cardiology, and partner organizations. [7] [8] [9] [10] From this perspective, we first address the increasing national and global burden of asthma and the need for up-to-date guidelines on managing asthma and then explore how the NHLBIrefocused agenda has now been applied for development of asthma CPGs. Specifically, we highlight the process for generating rigorous systematic evidence reviews and evidence syntheses to support the update of the 2007 National Asthma Education and Prevention Program Expert Panel Report 3 (EPR-3) on the diagnosis and management of asthma in adults. 
THE INCREASING NATIONAL AND GLOBAL BURDEN AND HEALTH CARE COSTS OF ASTHMA
Chronic respiratory diseases, such as asthma, are common and remain major contributors to impaired quality of life, reduced productivity, increased hospitalizations and in-hospital mortality, and increasing health care costs in the United States and worldwide. [12] [13] [14] For example, in 2015, asthma was the most prevalent chronic respiratory disease worldwide and had twice as many prevalent cases as chronic obstructive pulmonary disease. 12 Globally, the prevalence of asthma increased by 13% to more than 358 million persons from 1990 to 2015. 12 In the United States, the prevalence of asthma was estimated at 26 million persons in 2010, about 19 million adults aged 18 years and over and 7 million children aged 17 years or younger. 15 For the period 2008-2010, Akinbami et al 15 estimated that asthma prevalence was higher among children than adults and, compared with white persons, higher among multiple-race, black, and American Indian or Alaska Native persons. 15 Among patients with medically treated asthma, the total annual costs (including medical care, absenteeism, and mortality) is estimated at $82 billion.
14 Importantly, poorly controlled or uncontrolled asthma is common and associated with increased costs, increased health care use, and decreased economic productivity. 16 For example, using data from the 2008-2010 Medical Expenditure Panel Surveys, Sullivan et al 16 estimated that medical expenditures attributable to asthma were nearly $4423 greater for patients with uncontrolled asthma compared with those who did not have asthma. Additionally, frequency of hospital discharges was up to 4.6-fold greater, and emergency department visits were nearly 2-fold greater in patients with uncontrolled asthma compared with those without asthma. 16 Thus, timely access to updated CPGs for the treatment and control of asthma and the prevention of future asthma exacerbations is crucial.
NEED FOR AN UPDATED ASTHMA GUIDELINE
In 1989, the NHLBI initiated the National Asthma Education Program, which was subsequently renamed the National Asthma Education and Prevention Program (NAEPP). 17 In addition to its core mission of educating patients, providers, and the public about the signs, symptoms, and seriousness of asthma, the NAEPP has also overseen a strong partnership effort for the development of CPGs for the management of asthma and the creation of related tools and materials to facilitate guideline implementation.
In 1991, the NAEPP produced its first expert panel report on guidelines for the diagnosis and management of asthma. 18 This first CPG underwent a comprehensive update in 1997 and an update of selected topics in 2002. 19, 20 The most current guideline, published in 2007, is the expert panel's third report, 11 which was widely acclaimed as a ''scientific comprehensive review'' of the evidence, as well as a ''user-friendly'' summary report with recommendations for delivering ''the best care possible for both children and adults with asthma.'' 21 In 2014, an NHLBI Advisory Council Working Group was tasked with assessing the need for an update of the NAEPP EPR-3 and concluded that one was needed. 22 This working group also recommended that the 2007 Expert Panel Report should be updated on selected topics and that the NHLBI should continue to support and coordinate the production of the guidelines through the NAEPP 22 similar to the rationale and approach used to publish the guidelines on sickle cell disease. 23, 24 Six high-priority topics identified for the update included (1) adjustable medication dosing in patients with recurrent wheezing and asthma; (2) long-acting anti-muscarinic agents in asthma management as add-on to inhaled corticosteroids; (3) bronchial thermoplasty in adults with severe asthma; (4) fraction of exhaled nitric oxide in diagnosis, medication selection, and monitoring treatment response in asthmatic patients; (5) remediation of indoor allergens (house dust mites/pets) in asthma management; and (6) immunotherapy and asthma management. Topics 1 and 2 were subsequently combined, resulting in a total of 5 topical categories, as shown in Table I . [25] [26] [27] [28] [29] 
GENERATING EVIDENCE TO INFORM THE GUIDELINE UPDATE
In alignment with the stated commitment in the refocused agenda, the NHLBI engaged the Agency for Healthcare Research and Quality (AHRQ) and provided support for rigorous systematic evidence reviews through AHRQ Evidence-based Practice Centers. Protocols for the systematic evidence reviews have been published previously. 25, [27] [28] [29] The published protocols address formulation of the key questions that merit systematic literature review, the methods used, and the overall analytic framework. Completed systematic evidence review reports have been published on the AHRQ's Web site and include the effectiveness of indoor allergen reduction in the management of asthma 30 and the role of bronchial thermoplasty. 26 In addition, completed systematic review reports are now published for the effectiveness of indoor allergen reduction in the management of asthma, 31 the role of immunotherapy in the management of asthma, 32 the role of intermittent inhaled corticosteroids and long-acting muscarinic antagonists, 33 and the clinical utility of fraction of exhaled nitric oxide testing in asthmatic patients. 34 The critical questions for the systematic review topics are shown in Table I .
CHARTING THE PATH FROM EVIDENCE TO THE GUIDELINE UPDATE
Recently, the NHLBI established the NAEPP Federal Advisory Committee (FACA). The 15-member committee will assist the NHLBI in facilitating the effective exchange of information on asthma activities among federal agencies and partner organizations to enhance coordination of asthma-related programs and activities. The crucial role of the NAEPP and numerous nationallevel organizations in this endeavor cannot be overemphasized. These strategic partners include major scientific, professional, governmental, lay, and voluntary health organizations committed to advancing the clinical management of asthma. Working groups of the NAEPP FACAwill be established to focus on critical topics, such as dissemination and implementation and school health. The National Asthma Education and Prevention Program Expert Panel Report 4 Working Group (EPR-4 WG), which is coordinated, staffed, and supported by the NHLBI, plays the pivotal role in charting the path by taking the evidence generated and developing the guideline update.
The EPR-4 WG will use NHLBI-funded AHRQ evidence reports to update selected topics in the EPR-3 guidelines. The EPR-4 WG will update the clinical recommendations for the selected topics and grade the strength of each recommendation. 35 Guideline implementation will be considered while drafting the J ALLERGY CLIN IMMUNOL VOLUME 142, NUMBER 3 recommendations. 36 The EPR-4 WG will present updates to the NAEPP FACA committee in public meetings. The draft guideline report will undergo peer review and be available for public comments in advance of publication.
The EPR-4 WG will be composed of knowledgeable clinicianscientists with practical experience managing asthmatic patients across the age and severity spectrum. The working group will break into smaller groups as needed around the selected topics to develop clinical recommendations. The EPR-4 WG will meet both in person and through online meetings and follow the Institute of Medicine's recommendations and standards for using systematic evidence reviews in the development of trustworthy guidelines. 37 All EPR-4 WG members will follow financial disclosure and conflict of interest procedures using the standard author disclosure procedures outlined for manuscripts submitted to the Journal of Allergy and Clinical Immunology 38 and follow current best practices and standards for transparency and management of conflicts of interest, as recommended in the Institute of Medicine report. 37 The outcome of this sizable effort will be an update of the EPR-3 asthma guidelines and publication of the key recommendations in the Journal of Allergy and Clinical Immunology. Furthermore, novel approaches will be explored and incorporated, as appropriate, to facilitate guideline uptake, dissemination, and sustained implementation.
CONCLUSIONS
Developing or updating CPGs is a complex, costly, and timeconsuming process with many steps to ensure the validity, credibility, and robustness of the evidence to help guide practitioners, in this case on the optimal means to diagnose, treat, and manage asthmatic patients. These guidelines provide the critical step of truly translating discoveries into better health for all people. This rigorous process is necessary to make certain that clinical care is anchored in a solid evidence base and that taxpayer investment in National Institutes of Health-funded research is informing medical practice. As part of this process, and in addition to use of the published systematic evidence reviews, the expert panel will actively examine the overall asthma management for opportunities for improvement, as well as identify gaps in evidence and implementation to inform future research.
The NHLBI has had a long history of producing practice guidelines and through our refocused approach will continue to partner with all stakeholders to fill the need for heart, lung, and blood guidelines, where indicated. However, the NHLBI cannot stand alone in this area. All stakeholders must be involved and fully endorse and take an active role in implementing the best practices outlined in the guidelines. At the NHLBI, we look forward to working in partnership with the scientific community and related professional societies to ensure we chart a future of turning discoveries into improved health for all.
